Sep 20,2024

„beurer Academy“ App: Product knowledge and training for Beurer partners

Beurer has launched the "beurer Academy" app, designed to provide comprehensive support to specialist retailers by offering detailed information about the entire Beurer product range. Available in German and English, the free app is accessible via the Apple App Store and Google Play.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Aug 20,2024

Management of Prolonged Aerobic Exercise in People With Type 1 Diabetes on Automated Insulin Delivery Systems: A Randomized Controlled Study

A randomized controlled trial compared three strategies - raising glucose targets, consuming carbohydrates, and a combination of both—for managing blood glucose during prolonged aerobic exercise in individuals with type 1 diabetes using automated insulin delivery (AID) systems. Results showed that setting a higher glucose target before and during exercise was more effective at maintaining stable glucose levels compared to carbohydrate intake or a combination of both strategies. This approach led to improved time in target glucose range and lower insulin delivery. The study highlights the importance of personalized strategies to manage glycemia during physical activity for better diabetes care.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Aug 20,2024

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its Omnipod® products, will present at three upcoming investor conferences in September 2024. These include the Wells Fargo Healthcare Conference on September 4, the Morgan Stanley Global Healthcare Conference on September 6, and the Baird Global Healthcare Conference on September 10. Live audio webcasts will be available at investors.insulet.com/events, with replays accessible after the events.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 08,2024

Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Aug 14,2024

Empowering Hospitalized Patients With Diabetes: Implementation of a Hospital-wide CGM Policy With EHR-Integrated Validation for Dosing Insulin

A study at Stanford Health Care assessed the feasibility and acceptance of a hospital-wide continuous glucose monitoring (CGM) policy integrated with electronic health records (EHR) for insulin dosing. From November 2022 to August 2023, 135 patients used the protocol, which included personal CGMs like Dexcom G6 and FreeStyle Libre 2. Results showed that 87.8% of CGM validation attempts met accuracy criteria, and 80% of nurses preferred CGM over traditional fingerstick monitoring. Patient feedback was also positive, indicating effective interactions with nursing staff. The study concluded that the CGM policy is feasible and well-received, suggesting potential for broader implementation.

CLINICAL STUDY

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 23,2024

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

A study from the Australian ENDIA project investigated the use of continuous glucose monitoring (CGM) in young children at risk for type 1 diabetes (T1D). Between January 2021 and June 2023, researchers monitored 31 children with multiple islet autoimmunity (PM Ab+) and 24 control children, ages 4-5. Results showed that PM Ab+ children had higher glucose variability and spent more time with elevated glucose levels compared to controls. CGM was feasible and well-tolerated, revealing early signs of dysglycemia in young children at risk for T1D, consistent with findings in older age groups.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 23,2024

Dr. Eugene Wright Stresses Diabetes Care is a TEAM Endeavor

Dr. Eugene Wright, a diabetes specialist with over 40 years of experience, highlights the challenges in diabetes care, particularly in underserved communities where geographic and social disparities affect access to quality healthcare. He emphasizes the role of Stability Health in addressing these gaps by providing specialized care through endocrinologists, dieticians, and health coaches, helping both patients and clinicians manage diabetes more effectively.

View Analyst & Ambassador Comments
Go to original news
Aug 06,2024

Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial

A study found that closed-loop therapy (combining continuous glucose monitoring with automated insulin delivery) significantly improved glycemic control in people with type 2 diabetes compared to continuous subcutaneous insulin infusion (CSII) plus CGM. Time in range (TIR) increased from 61% to 76%, and other indicators like glucose variability and insulin doses also showed improvement. Sleep fragmentation improved during closed-loop treatment. The study concludes that closed-loop therapy offers better glycemic control than CSII + CGM for this population.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Sep 19,2024

ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND

Abbott (NYSE: ABT) declared a quarterly dividend of 55 cents per share, payable on Nov. 15, 2024, to shareholders of record by Oct. 15, 2024. This marks the 403rd consecutive dividend since 1924. Abbott has raised its dividend for 52 straight years and is part of the S&P 500 Dividend Aristocrats Index.

View Analyst & Ambassador Comments
Go to original news
Sep 16,2024

Continuous Glucose Monitoring Market Size Projected to Reach USD 8.82 Billion by 2032

The global Continuous Glucose Monitoring (CGM) market is projected to grow from USD 4.62 billion in 2023 to USD 8.82 billion by 2032, at a CAGR of 7.80%. This growth is driven by the rising prevalence of prediabetes, largely influenced by obesity and unhealthy lifestyles. Prediabetes, if untreated, can lead to type 2 diabetes and cardiovascular diseases, increasing the demand for CGM devices. Additionally, the growing elderly population, particularly vulnerable to diabetes, is expected to further boost market expansion. Key players in the market include Abbott, Dexcom, Medtronic, and Senseonics.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES